A Phase 2, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects
Latest Information Update: 19 Jun 2023
At a glance
- Drugs Florzolotau (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors APRINOIA Therapeutics
Most Recent Events
- 13 Jun 2023 Planned End Date changed from 1 Jan 2023 to 1 Feb 2025.
- 13 Jun 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Sep 2024.
- 13 Jun 2023 Status changed from recruiting to active, no longer recruiting.